A new poll has revealed the significant challenges GPs across Wales face in diagnosing gynaecological cancers, with almost half (49%) saying limited consultation time is a major concern.
The Censuswide Poll, commissioned by us in support of Claire’s Campaign, highlights views from GPs into how they respond to women who present with gynaecological symptoms that may be cancer.
The findings, based on responses from 100 frontline GPs across Wales, were commissioned to raise awareness about the reality of women’s experiences with gynaecological cancer in Wales.
Welsh Government data shows that targets for timely cancer treatment are not being met, while women report feeling dismissed, delayed and unheard when presenting with symptoms.
Our own insight shows the incidence rate for gynaecological cancer in Wales is higher than the UK average, as is the mortality rate.
Every year, there are nearly 1,200 cases of gynaecological cancers in Wales and around 470 women die of the disease.
In July 2022, only 38% of gynaecological cancers met the Single Cancer Pathway target (for no patients to wait longer than 62 days for treatment). Almost four years later, that figure stands at 50.7 per cent. Waiting times for gynaecological cancer treatment remain poorer than for many common cancers. While improvements have happened, progress has been slow and for many women, too late.
The poll highlights challenges in diagnosing gynaecological cancers, with systemic issues playing a critical role.
Among the key findings, GPs reported that early diagnosis was made more difficult because of:
- GPs fearing over-referring patients into an overburdened NHS = 34%
- Limited primary care consultation time = 49%
- Difficulty distinguishing cancer symptoms from common benign conditions (such as IBS) = 39%
- Limited access to timely diagnostic tests and specialist referrals
- A need for clearer clinical guidance and enhanced training
Early diagnosis is critical in improving survival rates for gynaecological cancers, but systemic barriers within primary care and referral pathways are making this increasingly challenging.
Gareth Howells, CEO at Tenovus Cancer Care, said: